PolyPid Ltd.

About PolyPid Ltd.

PolyPid is a global clinical-stage bio-pharmaceutical company focused on developing, manufacturing, and commercializing novel, locally administered therapies to improve surgical outcomes. Their proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology provides controlled and continuous delivery of medications at surgical sites.

Products & Services

PLEX Platform:A unique drug delivery platform made of alternating layers of polymers and lipids that entrap therapeutic drugs for prolonged delivery over days to months, accommodating various molecules like small molecules, proteins, peptides, and nucleic acids.

D-PLEX100:A lead product candidate delivering the broad-spectrum antibiotic doxycycline locally over four weeks to prevent surgical site infections (SSIs) in abdominal colorectal surgery, addressing resistant bacteria with minimal systemic exposure.

Cancer Research Program:A program focused on localized drug delivery solutions for cancer treatment, potentially decreasing tumor recurrence with reduced side effects, as seen with OncoPLEX.

Pain Research Program:A program aimed at developing localized solutions for pain management through controlled drug release.

Specialties

Localized Drug Delivery Surgical Site Infection Prevention Controlled Drug Release Polymer-Lipid Encapsulation Technology (PLEX) Cancer Therapy Solutions Pain Management Solutions

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 26700000 MR: - FA: $26.7 million FAN: 26700000	D: 2025-06-17 FD: 2025-06-17	-
2	RT: Private Placement T: - FT: Private Placement	A: 8100000 MR: - FA: 8.1 million FAN: 8100000	D: 2024-08-02 FD: 2024-08-02	-
3	RT: Private Placement T: - FT: Private Placement	A: 16200000 MR: - FA: 16.2 million FAN: 16200000	D: 2024-01-04 FD: 2024-01-04	2 investors
4	RT: Public Offering and Private Placement T: - FT: Public Offering and Private Placement	A: 11400000 MR: - FA: $11.4 million FAN: 11400000	D: 2023-03-31 FD: 2023-03-31	2 investors
5	RT: Underwritten Public Offering and Private Placement T: - FT: Underwritten Public Offering and Private Placement	A: 6200000 MR: - FA: $6.2 million FAN: 6200000	D: 2023-03-29 FD: 2023-03-29	1 investors

Warrant Exercise Latest

2025-06-17

$26.7M

Private Placement 2024-08-02

$8.1M

Private Placement 2024-01-04

$16.2M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

E

Erez Kachel

Head of Cardiothoracic Surgery

H

Hartzell V. Schaff

Stuart W. Harrington Professor of Surgery and Consultant in Cardiovascular Surgery

M

Moshe Salai

Head of the orthopedic division of the Tel-Aviv Sourasky Medical Center

R

Raanan Berger

Professor of Oncology

F

Frederick F. Lang

Chair of Neurosurgery and Director of the Brain Tumor Center at The University of Texas MD Anderson Cancer Center

M

Mitchel S. Berger

Berthold and Belle N. Guggenhime Professor of Neurological Surgery at the University of California, San Francisco (UCSF)

View 23 more team members with Pro

Unlock Full Team Directory

Recent News

PolyPid Ltd. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised